Lyell Immunopharma, Inc. (LYEL) EBITDA
- 2026-06-30: Basis Reported; EBITDA -$45.12M*; Operating income -$47.34M; Depreciation and amortization $2.22M*.
- 2026-03-31: Basis Reported; EBITDA -$41.93M; Operating income (m); Depreciation and amortization (m).
- 2025-12-31: Basis Reported; EBITDA -$125.25M; Operating income (m); Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA -$34.69M*; Operating income -$37.25M; Depreciation and amortization $2.57M*.
Complete source-backed ebitda history.
- Available history
- 2019-12-31 to 2026-03-31
- Data captured
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2026-06-30 | Reported | -$45.12M* | -$47.34M | $2.22M* | (m) | (m) | $256.00K* | -$33.92M* | (m) | $39.52M | (m) | (m) |
|---|
| 2026-03-31 | Reported | -$41.93M | (m) | (m) | (m) | -2096450.00% | $89.00K | -$38.51M | (m) | $36.60M | (m) | (m) |
|---|
| 2025-12-31 | Reported | -$125.25M | (m) | (m) | (m) | -2087450.00% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2025-09-30 | Reported | -$34.69M* | -$37.25M | $2.57M* | (m) | (m) | $62.00K* | -$28.58M* | (m) | $28.17M | (m) | (m) |
|---|
| 2025-06-30 | Reported | -$44.01M* | -$47.14M | $3.13M* | (m) | (m) | $168.00K* | -$34.46M* | (m) | $34.86M | (m) | (m) |
|---|
| 2025-03-31 | Reported | -$53.93M | (m) | (m) | (m) | -770371.43% | $246.00K | -$54.74M | (m) | $43.45M | (m) | (m) |
|---|
| 2024-12-31 | Reported | -$196.12M | (m) | (m) | (m) | -1782918.18% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2024-09-30 | Reported | -$45.83M* | -$50.51M | $4.68M* | (m) | (m) | $59.00K* | -$35.04M* | (m) | $39.50M | (m) | (m) |
|---|
| 2024-06-30 | Reported | -$46.63M* | -$51.53M | $4.90M* | (m) | (m) | $331.00K* | -$38.09M* | (m) | $40.26M | (m) | (m) |
|---|
| 2024-03-31 | Reported | -$50.55M | (m) | (m) | (m) | -1685033.33% | $30.00K | -$42.02M | (m) | $43.17M | (m) | (m) |
|---|
| 2023-12-31 | Reported | -$54.45M | (m) | (m) | (m) | -418853.85% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2023-09-30 | Reported | -$53.94M* | -$59.04M | $5.10M* | (m) | (m) | $195.00K* | -$37.69M* | (m) | $43.85M | (m) | (m) |
|---|
| 2023-06-30 | Reported | -$60.84M* | -$65.91M | $5.06M* | (m) | (m) | $933.00K* | -$39.16M* | (m) | $47.47M | (m) | (m) |
|---|
| 2023-03-31 | Reported | -$57.53M | (m) | (m) | (m) | -88506.15% | $1.53M | -$46.21M | (m) | $44.63M | (m) | (m) |
|---|
| 2022-12-31 | Reported | -$9.74M | (m) | (m) | (m) | -20.14% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2022-09-30 | Reported | -$61.82M* | -$66.44M | $4.62M* | (m) | (m) | $2.79M* | -$37.10M* | (m) | $41.61M | (m) | (m) |
|---|
| 2022-06-30 | Reported | -$33.09M* | -$37.26M | $4.17M* | (m) | (m) | $7.17M* | -$44.33M* | (m) | $43.72M | (m) | (m) |
|---|
| 2022-03-31 | Reported | -$64.39M | (m) | (m) | (m) | -11643.58% | $9.73M | -$47.85M | (m) | $35.83M | (m) | (m) |
|---|
| 2021-12-31 | Reported | -$42.97M | (m) | (m) | (m) | -1522.79% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2021-09-30 | Reported | -$45.07M* | -$49.16M | $4.09M* | (m) | (m) | $11.60M* | -$25.49M* | (m) | $31.43M | (m) | (m) |
|---|
| 2021-06-30 | Reported | -$59.70M* | -$62.71M | $3.01M* | (m) | (m) | $24.45M* | -$33.95M* | (m) | $46.45M | (m) | (m) |
|---|
| 2021-03-31 | Reported | -$53.41M | (m) | (m) | (m) | -2184.54% | $19.19M | -$33.60M | (m) | $41.53M | (m) | (m) |
|---|
| 2020-12-31 | Reported | -$38.07M | (m) | (m) | (m) | -1646.71% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2020-09-30 | Reported | -$35.74M* | -$36.84M | $1.10M* | (m) | (m) | $12.64M* | -$21.63M* | (m) | $24.50M | (m) | (m) |
|---|
| 2020-06-30 | Reported | (m) | -$102.57M | (m) | (m) | (m) | (m) | (m) | (m) | $97.15M | (m) | (m) |
|---|
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2025-12-31 | Reported | -$257.87M | (m) | (m) | (m) | -716291.67% | $780.00K | -$150.02M | (m) | (m) | (m) | $0.00 |
|---|
| 2024-12-31 | Reported | -$339.12M | (m) | (m) | (m) | -555940.98% | $464.00K | -$162.39M | (m) | (m) | (m) | (m) |
|---|
| 2023-12-31 | Reported | -$226.76M | (m) | (m) | (m) | -174429.23% | $2.69M | -$163.69M | (m) | $182.94M | (m) | (m) |
|---|
| 2022-12-31 | Reported | -$169.04M | (m) | (m) | (m) | -199.61% | $24.28M | -$169.56M | (m) | $159.19M | (m) | (m) |
|---|
| 2021-12-31 | Reported | -$201.15M | (m) | (m) | (m) | -1888.75% | $65.50M | -$126.25M | (m) | $138.69M | (m) | (m) |
|---|
| 2020-12-31 | Reported | -$207.64M | (m) | (m) | (m) | -2677.19% | $51.48M | -$160.87M | (m) | $182.24M | (m) | (m) |
|---|
| 2019-12-31 | Reported | -$100.83M | (m) | (m) | (m) | -15347.49% | $16.05M | $39.47M | (m) | $63.59M | (m) | (m) |
|---|